Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2386 to 2400 of 7681 results

  1. Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]

    In development [GID-TA11316] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Intrapartum Care - maternal hyponatremia

    In development [GID-NG10431] Expected publication date: TBC

    NICE guideline
    In development

  4. Nemolizumab for treating prurigo nodularis [ID6451]

    In development [GID-TA11566] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  5. Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

    In development [GID-TA11503] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development [GID-TA10994] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

    In development [GID-IPG10375] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  9. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia

    In development [GID-IPG10268] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  10. MRI-guided focused ultrasound subthalamotomy for treating Parkinson's

    In development [GID-IPG10402] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  11. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development [GID-TA11343] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

    In development [GID-TA11570] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  13. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]

    Awaiting development [GID-TA11627] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]

    Awaiting development [GID-TA11629] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development